Radar›Companies›Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 8
United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 8

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness
Readiness leaderOrganovo · 41
Strongest available path4D Molecular Therapeutics · -46.8%
Widest latest margin4D Molecular Therapeutics · -164.4%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1VIVS · Nasdaq

Organovo

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego$3.7M market cap
View full Companies Radar profile
41Cautious
Snapshot price$0.28as of page date
Monthly-close return-99.7%five-year window
FY2025 revenue$0.00BVivoSim Labs, INC.
Net margin-1727.8%FY2025
Prism attention29.9%share across these five
Filing track recordRevenue, USD billions
-93.4%
$0$0.0B$0.0B$0.0BFY2020: $0.002BFY2022: $0.002BFY2023: $0.000BFY2024: $0.000BFY2025: $0.000B20202022202320242025
FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -49.4%
52-week position0% through range
$0.26$5.30
News mentions1.2K
Community mentions0partial coverage
U.S.-scope patents273
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position17/100
Capital-event signal65/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 9 M&A involvements, 3 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2FDMT · Nasdaq

4D Molecular Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Emeryville, California$792.8M market cap
View full Companies Radar profile
40Cautious
Snapshot price$14.35as of page date
Monthly-close return-46.8%five-year window
FY2025 revenue$0.09B4D Molecular Therapeutics, Inc.
Net margin-164.4%FY2025
P/E snapshot-3.5xone ratio, not a verdict
Prism attention12.7%share across these five
Filing track recordRevenue, USD billions
+372.4%
$0$0.0B$0.1B$0.1BFY2021: $0.018BFY2022: $0.003BFY2023: $0.021BFY2024: $0.000BFY2025: $0.085B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 47.4%
52-week position76% through range
$5.97$16.93
News mentions525
Community mentions4partial coverage
U.S.-scope patents246
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal38/100
Management stability90/100
Market position0/100
Capital-event signal69/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3CVM · NYSE

Cel-Sci

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1983Vienna, Virginia$28.3M market cap
View full Companies Radar profile
40Cautious
Snapshot price$1.61as of page date
Monthly-close return-99.5%five-year window
FY2014 revenue$0.00BCEL SCI CORP
Net margin-10364.7%FY2014
P/E snapshot-0.3xone ratio, not a verdict
Prism attention21.2%share across these five
Filing track recordRevenue, USD billions
+3.7%
$0$0.0B$0.0B$0.0BFY2012: $0.000BFY2013: $0.000BFY2014: $0.000B201220132014
FY2012–FY2014 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.8%
52-week position6% through range
$0.89$12.68
News mentions881
Community mentions45partial coverage
U.S.-scope patents71
Prism Insights

What sits behind the readiness signal

Observed risk 10/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position5/100
Capital-event signal81/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4IMA · Nasdaq

Ikena Oncology

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2016Boston$57.0M market cap
View full Companies Radar profile
40Cautious
Snapshot price$5.02as of page date
Monthly-close return-96.7%five-year window
FY2025 revenue$0.00BImageneBio, Inc.
Net margin-5668.6%FY2025
P/E snapshot-1.2xone ratio, not a verdict
Prism attention7.1%share across these five
Filing track recordRevenue, USD billions
-97.4%
$0$0.0B$0.0B$0.0BFY2021: $0.031BFY2022: $0.016BFY2023: $0.009BFY2024: $0.009BFY2025: $0.001B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -59.9%
52-week position11% through range
$3.94$13.98
News mentions293
Community mentions4partial coverage
U.S.-scope patents201
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal52/100
Management stability90/100
Market position9/100
Capital-event signal37/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 5 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5FATE · Nasdaq

Fate Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego, California$291.2M market cap
View full Companies Radar profile
39Cautious
Snapshot price$2.43as of page date
Monthly-close return-95.9%five-year window
FY2025 revenue$0.01BFATE THERAPEUTICS INC
Net margin-2051.1%FY2025
P/E snapshot-2.5xone ratio, not a verdict
Prism attention29.1%share across these five
Filing track recordRevenue, USD billions
-88.1%
$0$0.0B$0.1B$0.1BFY2021: $0.056BFY2022: $0.096BFY2023: $0.064BFY2024: $0.014BFY2025: $0.007B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -41.3%
52-week position65% through range
$0.93$3.23
News mentions1.2K
Community mentions85partial coverage
U.S.-scope patents611
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse10/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

4D Molecular Therapeutics
-46.8%
Fate Therapeutics
-95.9%
Ikena Oncology
-96.7%
Cel-Sci
-99.5%
Organovo
-99.7%

Latest revenue

USD billions, official filing scope shown on each company card.

4D Molecular Therapeutics
$0.09B
Fate Therapeutics
$0.01B
Ikena Oncology
$0.00B
Organovo
$0.00B
Cel-Sci
$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

4D Molecular Therapeutics
-164.4%
Organovo
-1727.8%
Fate Therapeutics
-2051.1%
Ikena Oncology
-5668.6%
Cel-Sci
-10364.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Organovo
29.9%
Fate Therapeutics
29.1%
Cel-Sci
21.2%
4D Molecular Therapeutics
12.7%
Ikena Oncology
7.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Organovo leads the conversation

It holds 29.9% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.00B.

Price path

4D Molecular Therapeutics leads the available price paths

Its monthly-close return is -46.8% for the five-year window. At the other end, Organovo is -99.7% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

4D Molecular Therapeutics has the widest latest margin

Its FY2025 net margin is -164.4%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

4D Molecular Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -3.5x while its five-year window price return is -46.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · VIVS

Organovo

1,241available Prism news records

Prism top themes

Leadership & governance
12
Price action & investor response
12
Capital allocation & transactions
6
Legal, arbitration & regulatory
5
Macro demand & rates
4

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-22.2%77 latest 12m vs 99 prior 12m
2024-01: 5 mentions2024-02: 3 mentions2024-03: 1 mentions2024-04: 8 mentions2024-05: 14 mentions2024-06: 5 mentions2024-07: 4 mentions2024-08: 3 mentions2024-09: 6 mentions2024-10: 4 mentions2024-11: 6 mentions2024-12: 5 mentions2025-01: 7 mentions2025-02: 28 mentions2025-03: 14 mentions2025-04: 13 mentions2025-05: 7 mentions2025-06: 2 mentions2025-07: 0 mentions2025-08: 8 mentions2025-09: 2 mentions2025-10: 8 mentions2025-11: 5 mentions2025-12: 1 mentions2026-01: 9 mentions2026-02: 17 mentions2026-03: 8 mentions2026-04: 11 mentions2026-05: 7 mentions2026-06: 1 mentions2024-012026-06

Machine-classified coverage tone

95.9% positive+3.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

3d printer software 21additive manufacturing system 17wearable biotech 11biomaterials 113d printed drugs 83d printed implants 8anti-tnf therapy crohn's 7biologic agents crohn's 7

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-02–2026-06-01 · trend and themes shown through 2026-06
Areas of research · CVM

Cel-Sci

881available Prism news records

Prism top themes

Legal, arbitration & regulatory
21
Price action & investor response
18
Capital allocation & transactions
4
Earnings & financial performance
3
Macro demand & rates
1

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-79.0%52 latest 12m vs 248 prior 12m
2024-01: 3 mentions2024-02: 15 mentions2024-03: 13 mentions2024-04: 2 mentions2024-05: 13 mentions2024-06: 9 mentions2024-07: 9 mentions2024-08: 2 mentions2024-09: 8 mentions2024-10: 5 mentions2024-11: 3 mentions2024-12: 15 mentions2025-01: 7 mentions2025-02: 168 mentions2025-03: 16 mentions2025-04: 7 mentions2025-05: 8 mentions2025-06: 0 mentions2025-07: 5 mentions2025-08: 6 mentions2025-09: 5 mentions2025-10: 1 mentions2025-11: 0 mentions2025-12: 2 mentions2026-01: 3 mentions2026-02: 3 mentions2026-03: 2 mentions2026-04: 7 mentions2026-05: 15 mentions2026-06: 3 mentions2024-012026-06

Machine-classified coverage tone

93.8% positive-3.3 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

initial public offering 15stock price 14stock performance 14public offering 13stock surge 11share price 9relapsed hodgkin's immunotherapy 9cancer biomarkers 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-01 · trend and themes shown through 2026-06
Areas of research · FATE

Fate Therapeutics

1,208available Prism news records

Prism top themes

Leadership & governance
38
Price action & investor response
22
Legal, arbitration & regulatory
9
Capital allocation & transactions
7
Earnings & financial performance
6

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+20.3%166 latest 12m vs 138 prior 12m
2024-01: 10 mentions2024-02: 12 mentions2024-03: 9 mentions2024-04: 14 mentions2024-05: 22 mentions2024-06: 6 mentions2024-07: 14 mentions2024-08: 12 mentions2024-09: 2 mentions2024-10: 3 mentions2024-11: 20 mentions2024-12: 5 mentions2025-01: 4 mentions2025-02: 23 mentions2025-03: 20 mentions2025-04: 14 mentions2025-05: 15 mentions2025-06: 6 mentions2025-07: 6 mentions2025-08: 10 mentions2025-09: 8 mentions2025-10: 20 mentions2025-11: 7 mentions2025-12: 8 mentions2026-01: 9 mentions2026-02: 12 mentions2026-03: 21 mentions2026-04: 20 mentions2026-05: 37 mentions2026-06: 8 mentions2024-012026-06

Machine-classified coverage tone

94.2% positive+3.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cell-based therapies 61stem cell banking 54cell therapy 41pluripotent stem cells 27stem cell transplantation 22somatic cell therapy 12car-t cell therapy 9gene therapy rare diseases 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-19 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

CVM

Cel-Sci

45 mentions
Stock and valuation
23
Products, pricing and logistics
6

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 45 records remained after filtering.

FATE

Fate Therapeutics

85 mentions
Stock and valuation
47
Products, pricing and logistics
6
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 85 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

VIVS

Organovo

through 2025-04-03
Leadership changes 4Asset acquisitions 3Company announcements 1Earnings releases 1Lawsuits 1
  1. Earnings releases

    Organovo’s preliminary cash and cash equivalents balance was approximately $11.3 million as of the end of the fiscal year on March 31, 2025.

  2. Asset acquisitions

    Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.

  3. Company announcements

    Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced that it will effect a 1-for-12 reverse stock split of its issued and outstanding common stock that will become effective at 5:00 p.m. Eastern Time on Thursday, March 20, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FDMT

4D Molecular Therapeutics

through 2026-01-10
Leadership changes 4Earnings releases 2Listing / IPO 1
  1. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4D Molecular Therapeutics $40,000.00 10,711.88 -$160.87 million ($3.75) -2.00

  2. Leadership changes

    4D Molecular's previous chief financial officer, Uneek Mehra, left the Emeryville, Calif., company earlier this year to pursue other opportunities.

  3. Listing / IPO

    4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases, announced today that it priced an upsized underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CVM

Cel-Sci

through 2025-09-01
Listing / IPO 8Earnings releases 4Leadership changes 4Regulatory 4M&A 2
  1. Regulatory

    It has applied for Breakthrough Medicine Designation for Multikine, an immunotherapy for head and neck cancer, with the Saudi Food & Drug Authority.

  2. Listing / IPO

    CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock.

  3. Leadership changes

    Cel-Sci Corp. of Alexandria, Va., has hired Matthew Haines asdirector of investor relations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

IMA

Ikena Oncology

through 2025-07-25
Earnings releases 8M&A 4
  1. M&A

    today announced the completion of its previously announced merger with Ikena Oncology, Inc.

  2. Earnings releases

    Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ikena Oncology $659,000.00 82.75 -$68.17 million ($1.01) -1.12

  3. M&A

    Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,”) and Inmagene Biopharmaceuticals (“Inmagene”) announced they have entered into a definitive merger agreement.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FATE

Fate Therapeutics

through 2026-05-01
Company announcements 18Lawsuits 11Earnings releases 2Leadership changes 2Listing / IPO 1
  1. Company announcements

    today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee.

  2. Leadership changes

    Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025.

  3. Earnings releases

    now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence
2020 extracted base$194.20B–$477.15B
2033 extracted forecast$685.30B–$1.37T
Implied source CAGR8.5%
high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records
Latest 12m volume+9.8%10786 vs 9825 records
Positive classified tone41.7%+4.6 pp vs prior four quarters
2024-01: 892 mentions2024-02: 804 mentions2024-03: 821 mentions2024-04: 790 mentions2024-05: 1,080 mentions2024-06: 758 mentions2024-07: 563 mentions2024-08: 879 mentions2024-09: 628 mentions2024-10: 779 mentions2024-11: 620 mentions2024-12: 655 mentions2025-01: 712 mentions2025-02: 1,067 mentions2025-03: 1,362 mentions2025-04: 999 mentions2025-05: 803 mentions2025-06: 593 mentions2025-07: 966 mentions2025-08: 3,062 mentions2025-09: 751 mentions2025-10: 687 mentions2025-11: 634 mentions2025-12: 660 mentions2026-01: 312 mentions2026-02: 1,077 mentions2026-03: 634 mentions2026-04: 1,323 mentions2026-05: 87 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies
4,078
substance abuse education
3,736
opioid addiction and treatment
3,643
overdose prevention techniques
3,482
controlled substance regulations
3,381
substance abuse overdose fatalities
3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 36–43. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Scale and margin leadership sit with 4D Molecular Therapeutics and 4D Molecular Therapeutics

4D Molecular Therapeutics has the largest displayed latest revenue at $0.09B; 4D Molecular Therapeutics has the widest displayed latest margin at -164.4%.

Open 4D Molecular Therapeutics in Companies Radar
Comparisons
Anomalies

Fate Therapeutics has the widest attention-readiness rank gap

It ranks #2 by measured news attention (29.1%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Fate Therapeutics in Companies Radar

4D Molecular Therapeutics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +372.4% while its available monthly-close return is -46.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open 4D Molecular Therapeutics in Companies Radar
Explanations

Attention measures coverage volume, not quality

Organovo's 29.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Organovo in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Organovo's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 41/100 score.

Open Organovo in Companies Radar

Stress-test the largest divergence before forming a view

Compare 4D Molecular Therapeutics's profile with 4D Molecular Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open 4D Molecular Therapeutics in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon